These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 12698071)

  • 21. University of Miami Division of Clinical Pharmacology Therapeutic Rounds: managing hypertension in patients with kidney disease-implications for preservation of renal function.
    Preston RA; Fernandez L
    Am J Ther; 1998 Sep; 5(5):355-62. PubMed ID: 10099077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What have we learned from the current trials?
    Abbott KC; Bakris GL
    Med Clin North Am; 2004 Jan; 88(1):189-207. PubMed ID: 14871059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A; Ribstein J
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of diabetic nephropathy].
    Barna I
    Orv Hetil; 2003 Jan; 144(4):165-72. PubMed ID: 12621814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive drugs and diabetic nephropathy.
    Mehler PS; Schrier RW
    Curr Hypertens Rep; 1999; 1(2):170-7. PubMed ID: 10981062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension].
    Sawicki PT
    Wien Klin Wochenschr; 1995; 107(21):629-39. PubMed ID: 8578749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of hypertension in kidney diseases].
    Ferrari P; Bonny O
    Praxis (Bern 1994); 2003 Dec; 92(50):2145-52. PubMed ID: 14708253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood-pressure control preserves renal function.
    Frankel DH
    Lancet; 1998 May; 351(9115):1562. PubMed ID: 10326550
    [No Abstract]   [Full Text] [Related]  

  • 31. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
    Nosadini R; Abaterusso C; Dalla Vestra M; Bortoloso E; Saller A; Bruseghin M; Sfriso A; Trevisan M
    Nephrol Dial Transplant; 1998; 13 Suppl 8():44-8. PubMed ID: 9870425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection.
    Locatelli F; Del Vecchio L; Andrulli S; Colzani S
    Kidney Int Suppl; 2002 Dec; (82):S53-60. PubMed ID: 12410856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension.
    Morgan TO; Anderson AI; MacInnis RJ
    Am J Hypertens; 2001 Mar; 14(3):241-7. PubMed ID: 11281235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of chemical therapies for treating diabetic hypertension.
    Sarafidis PA; Alexandrou ME; Ruilope LM
    Expert Opin Pharmacother; 2017 Jun; 18(9):909-923. PubMed ID: 28480805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.
    Khan NA; McAlister FA; Rabkin SW; Padwal R; Feldman RD; Campbell NR; Leiter LA; Lewanczuk RZ; Schiffrin EL; Hill MD; Arnold M; Moe G; Campbell TS; Herbert C; Milot A; Stone JA; Burgess E; Hemmelgarn B; Jones C; Larochelle P; Ogilvie RI; Houlden R; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; Dechamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Tobe S; Touyz RM;
    Can J Cardiol; 2006 May; 22(7):583-93. PubMed ID: 16755313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.